Across TCGA pan-cancer cohorts, ANKRD65 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ANKRD65 data layer compared with 25 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher ANKRD65 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANKRD65 expression acts as an unfavorable survival marker.
COAD are the cancer types where ANKRD65 Mutation most reproducibly stratifies survival.